DOJ Classified Three Kratom-Related Opioids as Schedule I
Federal officials added modified kratom compounds to the most restrictive drug list in August 2026.
Updated on Oct. 9, 2026 in Substance Abuse
Live Poll
Should the federal government limit medical research access to substances that carry high addiction risks?
In August 2026, the U.S. Department of Justice and the Drug Enforcement Administration designated the synthetic substances MGPI, MGM-15, and MGM-16 as Schedule I controlled substances. This classification marks these modified versions of kratom-associated compounds as having high risks for addiction and respiratory depression.
Why it matters
By placing these compounds into the most restrictive federal category, authorities aim to address significant public health risks like potential respiratory failure. The shift creates stricter oversight requirements for laboratories, potentially complicating ongoing medical research into pain management and opioid dependence.
Federal authorities moved to restrict these three specific compounds based on identified risks of addiction and respiratory depression. While Schedule I status limits the substances' legal distribution, the long-term impact on research trial feasibility is not yet determined.
The players
Drug Enforcement Administration
The federal agency responsible for enforcing the Controlled Substances Act and managing drug classification.
U.S. Food and Drug Administration
The agency tasked with regulating public health and ensuring that only approved, safe substances are marketed as medical treatments.
The details
Schedule I status mandates that researchers obtain, store, and administer these compounds only under strict federal controls. While these restrictions apply to laboratory-modified and concentrated opioid compounds, they do not target the traditional botanical form of the kratom tree. The FDA maintains that kratom itself is not approved as a medication and is not lawfully marketed as a dietary supplement in the United States.
Timeline
August 2026: The DOJ and DEA officially classified MGPI, MGM-15, and MGM-16 as Schedule I controlled substances.
Health Landscape
This regulatory action follows the existing enforcement mechanisms established under the Controlled Substances Act to address emerging synthetic threats. It aligns with broader federal efforts to manage the opioid crisis by tightening oversight on laboratory-modified substances.
Because these substances are now subject to the most stringent federal controls, they remain illegal for personal use or as unapproved supplements. Any concerns about the health effects of kratom or its derivatives should be raised during a conversation with your physician.
The takeaway
Federal regulators have increased oversight on synthetic opioids derived from kratom to mitigate addiction and respiratory risks. Patients should remain cautious about any substances marketed as dietary supplements that claim to interact with the body as pain relievers or opioid alternatives.
Further reading
For more on federal drug oversight, visit Substance Abuse.
Source note: This article includes information reported by WRNJ Radio.
Live Poll
Should the federal government limit medical research access to substances that carry high addiction risks?
